BioCryst Pharmaceuticals announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older in Israel.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst presents real-world data on the effects of ORLADEYO on HAE attacks
- BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
- BioCryst to Present at Upcoming Investor Conferences
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology